ImmuCell Current Deferred Revenue from 2010 to 2026
| ICCC Stock | USD 6.63 0.01 0.15% |
Current Deferred Revenue | First Reported 2001-03-31 | Previous Quarter -1.8 B | Current Value 4.4 K | Quarterly Volatility 435.7 M |
Check ImmuCell financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ImmuCell's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.2 M, Interest Expense of 686.7 K or Total Revenue of 32 M, as well as many indicators such as Price To Sales Ratio of 1.69, Dividend Yield of 0.0 or PTB Ratio of 1.8. ImmuCell financial statements analysis is a perfect complement when working with ImmuCell Valuation or Volatility modules.
ImmuCell | Current Deferred Revenue | Build AI portfolio with ImmuCell Stock |
Analyzing ImmuCell's Current Deferred Revenue over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Current Deferred Revenue has evolved provides context for assessing ImmuCell's current valuation and future prospects.
Latest ImmuCell's Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of ImmuCell over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. ImmuCell's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ImmuCell's overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
ImmuCell Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 163,408 | |
| Geometric Mean | 75,716 | |
| Coefficient Of Variation | 81.41 | |
| Mean Deviation | 126,251 | |
| Median | 248,424 | |
| Standard Deviation | 133,037 | |
| Sample Variance | 17.7B | |
| Range | 283.9K | |
| R-Value | 0.81 | |
| Mean Square Error | 6.6B | |
| R-Squared | 0.65 | |
| Significance | 0.000096 | |
| Slope | 21,216 | |
| Total Sum of Squares | 283.2B |
ImmuCell Current Deferred Revenue History
About ImmuCell Financial Statements
ImmuCell stakeholders use historical fundamental indicators, such as ImmuCell's Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although ImmuCell investors may analyze each financial statement separately, they are all interrelated. For example, changes in ImmuCell's assets and liabilities are reflected in the revenues and expenses on ImmuCell's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in ImmuCell. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 261.5 K | 248.4 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ImmuCell offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ImmuCell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immucell Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immucell Stock:Check out the analysis of ImmuCell Correlation against competitors. For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Will Biotechnology sector continue expanding? Could ImmuCell diversify its offerings? Factors like these will boost the valuation of ImmuCell. Market participants price ImmuCell higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every ImmuCell data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.63) | Earnings Share 0.21 | Revenue Per Share | Quarterly Revenue Growth 0.178 | Return On Assets |
Understanding ImmuCell requires distinguishing between market price and book value, where the latter reflects ImmuCell's accounting equity. The concept of intrinsic value - what ImmuCell's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push ImmuCell's price substantially above or below its fundamental value.
Please note, there is a significant difference between ImmuCell's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmuCell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, ImmuCell's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.